RudaCure, una empresa especializada en el desarrollo de tratamientos para trastornos sensoriales, drew significant attention at a major internacional rheumatology conferencia.
Según RudaCure Inc. (CEO Yongho Kim), la empresa presentó preclinical eficacia resultados of its osteoartritis tratamiento candidato under desarrollo at the American College of Rheumatology (ACR) Annual Meeting, celebrado en San Diego, USA from the 10th to the 15th, receiving considerable interest from attendees.
The compuesto discovered by RudaCure features a mechanism that selectively inhibits TRPV1 activation. In prior studies, it demostró TRPV1 inhibitory effects and reduced pain in dolor crónico animal models. Notablemente, unlike existing TRPV1 antagonists, it did not cause abnormal hyperthermia.
Además de the poster presentación, RudaCure was also invited to the BCRC (Basic & Clinical Research Conference) session—one of the key programas at ACR 2023—where la empresa's cumulative investigación findings were presentó directly to the audience.
RudaCure El CEO Yongho Kim declaró: "By moving away from traditional desarrollo de fármacos methods with low success rates in the pain field and leveraging computational science, we were able to rapidly identify compuesto líders," adding, "En particular, having a diverse range of pain models allowed us to quickly and accurately address desarrollo de fármacos and efecto secundario challenges, which is a key advantage."
He further señaló, "Based on these investigación resultados, we plan to expand the indications for various pain conditions," and "También estamos pursuing the desarrollo of a drug that can suppress pain for several months with a single administration through formulación investigación."
Source: Pharmnews (http://www.pharmnews.com)
http://www.biospectator.com/view/news_view.php?varAtcId=20336